01
JCI · 2017
Humanized mouse models
Independent studies reported immune-function, exhaustion-marker and reservoir-related findings in experimental settings.
Immunotherapy · Therapeutic vaccines · IFN-α modulation
Reprogramming immunity through IFN-α modulation.
Dys-Immune Therapeutics is a French biotechnology company developing novel immunotherapies based on the modulation of interferon-α and cytokine network dysregulation.
40+ years of research
Proprietary IFN-α platform
International expertise
Lead program: Vaxiferon®
Our mission
Translating decades of immunology research into a new generation of therapeutic approaches.
We are focused on developing treatments for severe chronic diseases by targeting dysfunctional immune signaling. Our work combines scientific heritage with a disciplined path toward clinical development.
40+Research heritage
IFN-αPlatform focus
GlobalScientific expertise
The science
IFN-α: a key regulator of immune balance
Interferon-α is central to antiviral immunity. Yet chronic or dysregulated signaling may contribute to persistent activation and immune dysfunction.
01
Chronic viral infection
Persistent antigenic pressure may sustain immune activation.
02
IFN-α modulation
An investigational intervention point designed to address dysregulated signaling.
03
Immune balance
The intended biological direction is a more functional immune equilibrium.
Lead program · Investigational
Vaxiferon®
An investigational therapeutic vaccine concept for HIV combining HIV-specific immune stimulation with modulation of excessive IFN-α activity.
Component 01
HIV antigens
Designed to stimulate HIV-specific immune responses.
Component 02
Anti-IFN-α immunization component
Designed to modulate excessive IFN-α activity.
Intended biological directionStrengthened HIV-specific immunity
+Pathway objectiveIFN-α modulation
Development objectiveSupport the immunological conditions required for durable control of HIV.
The development objective is investigational. Clinical efficacy has not been established, and Vaxiferon® is not an approved medicine.
Program overviewEvidence
From mechanism to translation.
A staged body of published experimental evidence and related human pathway experience supports further investigation of IFN-α modulation.
02
JCI Insight · 2022
Rhesus macaques
Published SIV research examined viral DNA measurements, immune signaling and immunological or metabolic parameters.
03
Related anti-IFN-α approach
Human pathway experience
AGS-009 provides translational information from another indication; it does not establish Vaxiferon® safety.
04
Investigational program
Vaxiferon® development
The evidence supports the rationale for future clinical evaluation; efficacy has not been established.